Lineage Cell Therapeutics, Inc. Annual Return On Equity in % from 2012 to 2023

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Return On Equity history and growth rate from 2012 to 2023.
  • Lineage Cell Therapeutics, Inc. Return On Equity for the quarter ending June 30, 2024 was -36.3 %, a 19.4% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Return On Equity for 2023 was -32 %, a 3.85% increase from 2022.
  • Lineage Cell Therapeutics, Inc. annual Return On Equity for 2022 was -33.2 %, a 13% increase from 2021.
  • Lineage Cell Therapeutics, Inc. annual Return On Equity for 2021 was -38.2 %, a 79.2% decline from 2020.
Return On Equity, Annual (%)
Return On Equity, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date
2023 -32 +1.28 +3.85% Jan 1, 2023 Dec 31, 2023
2022 -33.2 +4.95 +13% Jan 1, 2022 Dec 31, 2022
2021 -38.2 -16.9 -79.2% Jan 1, 2021 Dec 31, 2021
2020 -21.3 -12.3 -136% Jan 1, 2020 Dec 31, 2020
2019 -9.01 +30.2 +77% Jan 1, 2019 Dec 31, 2019
2018 -39.2 -28.4 -264% Jan 1, 2018 Dec 31, 2018
2017 -10.8 -42.7 -134% Jan 1, 2017 Dec 31, 2017
2016 31.9 +104 Jan 1, 2016 Dec 31, 2016
2015 -72.3 +2.88 +3.83% Jan 1, 2015 Dec 31, 2015
2014 -75.2 +57.6 +43.4% Jan 1, 2014 Dec 31, 2014
2013 -133 -63.5 -91.6% Jan 1, 2013 Dec 31, 2013
2012 -69.3 Jan 1, 2012 Dec 31, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.